Bladder Cancer
Conditions
Interventions
experimental group:intravesical hematoporphyrin infusion photodynamic therapy combined with pirarubicin hydrochloride infusion chemotherapy
Sponsors
Shenzhen Hospital, Cancer Hospital, Chinese Academy of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. The patient aged 18-80 years, and confirmed by histology as middle-high-risk non-muscular invasive bladder cancer. 2. ECOG score: 0-1 points; 3. Expected survival period >= 2 years; 4. Complete screening related examinations (blood routine, coagulation function, liver and kidney function, infectious disease screening, 12-lead electrocardiogram, urinary system B-ultrasound, pelvic enhanced CT or MR, histopathological examination), and no surgical contraindications; 5. Volunteer to participate in this trial and sign an informed consent form;
Exclusion criteria
Exclusion criteria: 1. Those who are known to be allergic to test drugs or related drugs; 2. Have a history of bladder contracture or the functional bladder volume is less than 100mL; 3. Patients with severe urethral stricture that cannot be inserted into a cystoscope; 4. Other tumors of the genitourinary system or other organs are found during the inspection; 5. Those who suffer from severe coagulation function, liver and kidney function, hematopoietic dysfunction, etc. who cannot tolerate surgical treatment 6. Those who suffer from immunocompromised, acquired, or congenital immunodeficiency diseases; 7. Suffering from various mental disorders, severe cardiovascular and cerebrovascular diseases, cardiopulmonary dysfunction, etc. who cannot tolerate surgery; 8. There are active infections: acute pneumonia, active tuberculosis, severe urinary tract infection; 9. Women during pregnancy and lactation; 10. Participated in other clinical trials in the past 30 days; 11. Patients judged by the investigator as unsuitable to participate in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Relapse-Free Survival, RFS; | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression-Free Survival, PFS; | — |
Countries
China
Contacts
Public ContactTian Jun
Shenzhen Hospital, Cancer Hospital, Chinese Academy of Medical Sciences
Outcome results
None listed